Skip to main
PHVS

Pharvaris B.V. (PHVS) Stock Forecast & Price Target

Pharvaris B.V. (PHVS) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 20%
Buy 70%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

Pharvaris is a promising late-stage biopharmaceutical company with a strong pipeline of potential treatments for hereditary angioedema. Their novel oral bradykinin B2 receptor antagonists have shown positive data in Phase 2 studies for both prophylaxis and treatment of HAE attacks, and the company is currently enrolling a pivotal Phase 3 study for HAE treatment and planning a Phase 3 study for HAE prevention. With promising results and a differentiated asset in the HAE space, Pharvaris has the potential for blockbuster success, making it a strong investment opportunity.

Bears say

Pharvaris is a small biopharmaceutical company that is developing a promising drug, deucrictibant, for the treatment of hereditary angioedema (HAE) attacks. However, the company may face challenges in gaining regulatory approval due to potential changes in requirements or the need for additional data. This could limit their ability to gain market traction and negatively impact their financials in the future. Hence, a negative outlook is justified for this stock.

Pharvaris B.V. (PHVS) has been analyzed by 10 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 70% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pharvaris B.V. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pharvaris B.V. (PHVS) Forecast

Analysts have given Pharvaris B.V. (PHVS) a Buy based on their latest research and market trends.

According to 10 analysts, Pharvaris B.V. (PHVS) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pharvaris B.V. (PHVS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.